Aspirin-induced AMP-activated protein kinase activation regulates the proliferation of vascular smooth muscle cells from spontaneously hypertensive rats

Biochemical and Biophysical Research Communications

Volumn 408, Issue 2, 2011, Pages 312-317

  Sung, Jin Young ^a   Choi, Hyoung Chul ^a  

^a Yeungnam University College of Medicine   (South Korea)

Author keywords

AMP activated protein kinase (AMPK); Aspirin; Spontaneously hypertensive rats (SHR); Vascular smooth muscle cells (VSMCs); Wistar kyoto rats (WKY)

Indexed keywords

ACETYL COENZYME A CARBOXYLASE; ACETYLSALICYLIC ACID; CELL CYCLE PROTEIN; COMPOUND C; CYCLIN D; CYCLIN E; ENZYME INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; P RB PROTEIN; PROTEIN P21; PROTEIN P53; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; GENETIC TRANSFECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REGULATORY MECHANISM; SPONTANEOUSLY HYPERTENSIVE RAT; VASCULAR SMOOTH MUSCLE; WESTERN BLOTTING; WISTAR KYOTO RAT;

AMP-ACTIVATED PROTEIN KINASES; ANIMALS; ASPIRIN; CELL PROLIFERATION; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; RATS; RATS, INBRED SHR; RATS, INBRED WKY; TUMOR SUPPRESSOR PROTEIN P53;

RATTUS;

EID: 79955663918     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2011.04.027     Document Type: Article

References (33)

1. Owens G.K., Kumar M.S., Wamhoff B.R. Molecular regulation of vascular smooth muscle cell differentiation in development and disease. Physiol. Rev. 2004, 84:767-801.
2. Braun-Dullaeus R.C., Mann M.J., Dzau V.J. Cell cycle progression: new therapeutic target for vascular proliferative disease. Circulation 1998, 98:82-89.
3. Li P.G., Xu J.W., Ikeda K., Kobayakawa A., Kayano Y., Mitani T. Caffeic acid inhibits vascular smooth muscle cell proliferation induced by angiotensin II in stroke-prone spontaneously hypertensive rats. Hypertens. Res. 2005, 28:369-377.
4. Xu C., Lee S., Singh T.M., Sho E., Li X., Sho M. Molecular mechanisms of aortic wall remodeling in response to hypertension. J. Vasc. Surg. 2001, 33:570-578.
5. Ollinger R., Bilban M., Erat A., Froio A., McDaid J., Tyagi S. Bilirubin: a natural inhibitor of vascular smooth muscle cell proliferation. Circulation 2005, 112:1030-1039.
6. Hardie D.G., Carling D. The AMP-activated protein kinase - fuel gauge of the mammalian cell. Eur. J. Biochem. 1997, 246:259-273.
7. Hardie D.G., Scott J.W., Pan D.A., Hudson E.R. Management of cellular energy by the AMP-activated protein kinase system. FEBS Lett. 2003, 546:113-120.
8. Luo Z., Saha A.K., Xiang X., Ruderman N.B. AMPK, the metabolic syndrome and cancer. Trends Pharmacol. Sci. 2005, 26:69-76.
9. Hardie D.G. The AMP-activated protein kinase pathway - new players upstream and downstream. J. Cell Sci. 2004, 117:5479-5487.
10. Igata M., Motoshima H., Tsuruzoe K., Kojima K., Matsumura T., Kondo T. Adenosine monophosphate-activated protein kinase suppresses vascular smooth muscle cell proliferation through the inhibition of cell cycle progression. Circ. Res. 2005, 97:837-844.
11. Lizcano J.M., Göransson O., Toth R., Deak M., Morrice N.A., Boudeau J. LKB1 is a master kinase that activates 13 kinases of the AMPK subfamily, including MARK/PAR-1. EMBO J. 2004, 23:833-843.
12. Bolster D.R., Crozier S.J., Kimball S.R., Jefferson L.S. AMP-activated protein kinase suppresses protein synthesis in rat skeletal muscle through down-regulated mammalian target of rapamycin (mTOR) signaling. J. Biol. Chem. 2002, 277:23977-23980.
13. Motoshima H., Goldstein B.J., Igata M., Araki E. AMPK and cell proliferation-AMPK as a therapeutic target for atherosclerosis and cancer. J. Physiol. 2006, 574:63-71.
14. Brooks G., Yu X.M., Wang Y., Crabbe M.J., Shattock M.J., Harper J.V. Non-steroidal anti-inflammatory drugs (NSAIDs) inhibit vascular smooth muscle cell proliferation via differential effects on the cell cycle. J. Pharm. Pharmacol. 2003, 55:519-526.
15. Bernhardt J., Rogalla K., Lüscher T.F., Bühler F.R., Resink T.J. Acetylsalicylic acid, at high concentrations, inhibits vascular smooth muscle cell proliferation. J. Cardiovasc. Pharmacol. 1993, 21:973-976.
16. Yang H.M., Kim H.S., Park K.W., You H.J., Jeon S.I., Youn S.W. Celecoxib, a cyclooxygenase-2 inhibitor, reduces neointimal hyperplasia through inhibition of Akt signaling. Circulation 2004, 110:301-308.
17. Shukla N., Angelini G.D., Ascione R., Talpahewa S., Capoun R., Jeremy J.Y. Nitric oxide donating aspirins: novel drugs for the treatment of saphenous vein graft failure. Ann. Thorac. Surg. 2003, 75:1437-1442.
18. Tanner F.C., Greutert H., Barandier C., Frischknecht K., Lüscher T.F. Different cell cycle regulation of vascular smooth muscle in genetic hypertension. Hypertension 2003, 42:184-188.
19. Resink T.J., Scott-Burden T., Bauer U., Buhler F.R. Increased proliferation fate and phosphoinositide turnover in cultured smooth muscle cells from spontaneously hypertensive rats. J. Hypertens. 1987, 5:S145-S148.
20. Choi H.C., Song P., Xie Z., Wu Y., Xu J., Zhang M., Dong Y., Wang S., Lau K., Zou M.H. Reactive nitrogen species is required for the activation of the AMP-activated protein kinase by statin in vivo. J. Biol. Chem. 2008, 283:20186-20197.
21. Xie Z., Dong Y., Scholz R., Neumann D., Zou M.H. Phosphorylation of LKB1 at serine 428 by protein kinase C-zeta is required for metformin-enhanced activation of the AMP-activated protein kinase in endothelial cells. Circulation 2008, 117:952-962.
22. Nagata D., Takeda R R., Sata M., Satonaka H., Suzuki E., Nagano T., Hirata Y. AMP-activated protein kinase inhibits angiotensin II-stimulated vascular smooth muscle cell proliferation. Circulation 2004, 110:444-451.
23. Zang M., Xu S., Maitland-Toolan K.A., Zuccollo A., Hou X., Jiang B., Wierzbicki M., Verbeuren T.J., Cohen R.A. Polyphenols stimulate AMP-activated protein kinase, lower lipids, and inhibit accelerated atherosclerosis in diabetic LDL receptor-deficient mice. Diabetes 2006, 55:2180-2191.
24. Wang S., Xu J., Song P., Viollet B., Zou M.H. In vivo activation of AMP-activated protein kinase attenuates diabetes-enhanced degradation of GTP cyclohydrolase I. Diabetes 2009, 58:1893-1901.
25. Marra D.E., Simoncini T., Liao J.K. Inhibition of vascular smooth muscle cell proliferation by sodium salicylate mediated by upregulation of p21(Waf1) and p27(Kip1). Circulation 2000, 102:2130-2144.
26. Xie Z., Dong Y., Zhang M., Cui M.Z., Cohen R.A., Riek U., Neumann D., Schlattner U., Zou M.H. Activation of protein kinase C zeta by peroxynitrite regulates LKB1-dependent AMP-activated protein kinase in cultured endothelial cells. J. Biol. Chem. 2006, 281:6366-6375.
27. Shen Q.W., Zhu M.J., Tong J., Ren J., Du M. Ca2+/calmodulin-dependent protein kinase kinase is involved in AMP-activated protein kinase activation by alpha-lipoic acid in C2C12 myotubes. Am. J. Physiol. Cell Physiol. 2007, 293:C1395-C1403.
28. Momcilovic M., Hong S.P., Carlson M. Mammalian TAK1 activates Snf1 protein kinase in yeast and phosphorylates AMP-activated protein kinase in vitro. J. Biol. Chem. 2006, 281:25336-25343.
29. Park S.H., Gammon S.R., Knippers J.D., Paulsen S.R., Rubink D.S., Winder W.W. Phosphorylation-activity relationships of AMPK and acetyl-CoA carboxylase in muscle. J. Appl. Physiol. 2002, 92:2475-2482.
30. Herlitz J., Tóth P.P., Naesdal J. Low-dose aspirin therapy for cardiovascular prevention: quantification and consequences of poor compliance or discontinuation. Am. J. Cardiovasc. Drugs 2010, 10:125-141.
31. Ford R.J., Rush J.W. Endothelium-dependent vasorelaxation to the AMPK activator AICAR is enhanced in aorta from hypertensive rats and is NO and EDCF dependent. Am. J. Physiol. Heart Circ. Physiol. 2011, 300:H64-H75.
32. Zou M.H., Wu Y. AMP-activated protein kinase activation as a strategy for protecting vascular endothelial function. Clin. Exp. Pharmacol. Physiol. 2008, 35:535-545.
33. Zhang W.B., Wang Z., Shu F., Jin Y.H., Liu H.Y., Wang Q.J., Yang Y. Activation of AMP-activated protein kinase by temozolomide contributes to apoptosis in glioblastoma cells via p53 activation and mTORC1 inhibition. J. Biol. Chem. 2010, 285:40461-40471.